The endocannabinoid system: Current pharmacological research and therapeutic possibilities

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 2, 2006, Pages 124-134

  Jonsson, Kent Olov ^a   Holt, Sandra ^a   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 [2,3 DICHLOROBENZOYL] 5 METHOXY 2 METHYL [2 (MORPHOLIN 4 YL)ETHYL] 1H INDOLE; 2 IODO 5 NITROPHENYL[1 (1 METHYLPIPERIDINE 2 YL METHYL) 1H INDOL 3 YL]METHANONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1,1 DIMETHYLBUTYL) 6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO[B,D]PYRAN; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYL BICYCLO[3.1.1]HEPT 2 ENE 2 METHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 4 AMINOBUTYRIC ACID RECEPTOR; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ADENYLATE CYCLASE; AM 1241; ANANDAMIDE; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; GW 405833; HU 308; JWH 133; N (2 CHLOROETHYL)EICOSATETRAENAMIDE; RIMONABANT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; CELL MEMBRANE DEPOLARIZATION; CELL STRAIN HL 60; CORONARY ARTERY ATHEROSCLEROSIS; DRUG BINDING SITE; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG RESEARCH; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; GLAUCOMA; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; INTESTINAL DYSMOTILITY; LIFE CYCLE; MAST CELL DEGRANULATION; NEUROPATHIC PAIN; NEUROPHARMACOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; SHORT SURVEY; SIGNAL TRANSDUCTION; SMOKING CESSATION;

AMIDOHYDROLASES; ANIMALS; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; RECEPTORS, CANNABINOID;

ANIMALIA;

EID: 33645084256     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_376.x     Document Type: Short Survey

References (143)

1. Adams I. B. B. R. Martin Cannabis: pharmacology and toxicology in animals and humans Addiction 1996 91 1585 1614 review
2. Al-Hayani A. K. N. Wease R. A. Ross R. G. Pertwee S. N. Davies The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice Neuropharmacology 2001 41 1000 1005
3. Ates M. M. Hamza K. Seidel C. E. Kotalla C. Ledent H. Gühring Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test Eur. J. Neurosci. 2003 17 597 604
4. Azad S. C. K. Monory G. Marsicano B. F. Cravatt B. Lutz W. Zieglgänsberger G. Rammes Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling J. Neurosci. 2004 24 9953 9961
5. Baker D. G. Pryce J. L. Croxford P. Brown R. G. Pertwee A. Makriyannis A. Khanolkar L. Layward F. Fezza T. Bisogno V. Di Marzo Endocannabinoids control spasticity in a multiple sclerosis model FASEB J. 2001 15 300 302
6. 3A receptors: probable involvement of an allosteric modulatory site Brit. J. Pharmacol. 2002 137 589 596
7. Begg M. P. Pacher S. Bátkai D. Osei-Hyiaman L. Offertáler F. M. Mo J. Liu G. Kunos Evidence for novel cannabinoid receptors Pharmacol. Therap. 2005 106 133 145
8. Berger C. P. C. Schmid W.-R. Schabitz M. Wolf S. Schwab H. H. O. Schmid Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J. Neurochem. 2004 88 1159 1167
9. Berman J. S. C. Symonds R. Birch Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Pain 2004 112 299 306
10. Bifulco M. C. Laezza M. Valenti A. Ligresti G. Portella V. Di Marzo A new strategy to block tumor growth by inhibiting endocannabinoid inactivation FASEB J. 2004 18 1606 1608
11. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Biochem. J. 2000 351 817 824
12. Bojesen I. N. H. S. Hansen Membrane transport of anandamide through resealed human red blood cell membranes J. Lipid Res. 2005 46 1652 1659
13. Bouaboula M. S. Hilairet J. Marchand L. Fajas G. Le Fur P. Casellas Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation Eur. J. Pharmacol. 2005 517 174 181
14. Bradshaw H. B. J. M. Walker The expanding field of cannabimimetic and related lipid mediators Brit. J. Pharmacol. 2005 144 459 465
15. Brown A. J. S. Ueno K. Suen S. J. Dowell A. Wise Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2005 p. 16
16. Casanova M. L. C. Blázquez J. Martínez-Palacio C. Villanueva M. J. Fernández-Aceñero J. W. Huffman J. L. Jorcano M. Guzmán Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors J. Clin. Invest. 2003 111 43 50
17. Clayton N. F. H. Marshall C. Bountra C. T. O'Shaughnessy CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain Pain 2002 96 253 260
18. Cleland J. G. F. J. Ghosh N. Freemantle G. C. Kaye M. Nasir A. L. Clark A. P. Coletta Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure Eur. J. Heart Failure 2004 6 501 508
19. Costa B. M. Colleoni A. E. Trovato F. Comelli C. Franke G. Giognoni Anandamide transport and hydrolysis as targets for the treatment of neuropathic pain: effects of AM404 and URB597 in rats with chronic constriction injury of the sciatic nerve. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2005 p. 33
20. Craib S. J. H. C. Ellington R. G. Pertwee R. A. Ross A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus Brit. J. Pharmacol. 2001 134 30 37
21. Cravatt B. F. A. Saghatelian E. G. Hawkins A. B. Clement M. H. Bracey A. H. Lichtman Functional disassociation of the central and peripheral fatty acid amide signaling systems Proc. Natl. Acad. Sci. USA 2004 101 10821 10826
22. Cravatt B. F. K. Demarest M. P. Patricelli M. H. Bracey D. K. Giang B. R. Martin A. H. Lichtman Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. USA 2001 98 9371 9376
23. Darmani N. A. A. A. Izzo B. Degenhardt M. Valenti G. Scaglione R. Capasso I. Sorrentini V. Di Marzo Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies Neuropharmacology 2005 48 1154 1163
24. + channels but not changes in cAMP signaling contribute to the inhibition of glutamate release by cannabinoid receptors in cerebrocortical nerve terminals Neuropharmacology 2005 48 547 557
25. Deutsch D. G. S. A. Chin Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist Biochem. Pharmacol. 1993 46 791 796
26. Deutsch D. G. S. T. Glaser J. M. Howell J. S. Kunz R. A. Puffenbarger C. J. Hillard N. Abumrad The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase J. Biol. Chem. 2001 276 6967 6973
27. Devane W. A. F. A. Dysarz R. M. Johnson L. S. Melvin A. C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 1988 34 605 613
28. Devane W. A. L. Hanus A. Breuer R. G. Pertwee L. G. Stevenson G. Griffin D. Gibson A. Mandelbaum A. Etinger R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992 258 1946 1949
29. Diana M. A. A. Marty Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE) Brit. J. Pharmacol. 2004 142 9 19 review
30. Di Marzo V. A. Fontana H. Cadas S. Schinelli G. Cimino J. C. Schwartz D. Piomelli Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 1994 372 686 691
31. Di Marzo V. M. Bifulco L. De Petrocellis The endocannabinoid system and its therapeutic exploitation Nature Rev. Drug Dis. 2004 3 771 784 review
32. Dinh T. P. D. Carpenter F. M. Leslie T. F. Freund I. Katona S. L. Sensi S. Kathuria D. Piomelli Brain monoglyceride lipase participating in endocannabinoid inactivation Proc. Natl. Acad. Sci. USA 2002 99 10819 10824
33. Dinis P. A. Charrua A. Avelino M. Yaqoob S. Bevan I. Nagy F. Cruz Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis J. Neurosci. 2004 24 11253 11263
34. Drmota T. P. Greasley T. Groblewski Screening assays for cannabinoid-ligand-type modulators of GPR55 Patent number WO 2004/074844 A1
35. Fegley D. S. Kathuria R. Mercier C. Li A. Goutopoulos A. Makriyannis D. Piomelli Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172 Proc. Natl. Acad. Sci. USA 2004 101 8756 8761
36. Fowler C. J. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects Brain Res. Rev. 2003 41 26 43 review
37. Fowler C. J. G. Tiger A. Ligresti M. L. López-Rodríguez V. Di Marzo Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - a difficult issue to handle Eur. J. Pharmacol. 2004 492 1 11
38. Fowler C. J. S. Holt O. Nilsson K.-O. Jonsson G. Tiger S. O. P. Jacobsson The endocannabinoid signaling system: pharmacological and therapeutic aspects Pharmacol. Biochem. Behav. 2005 81 248 262 review
39. Fowler C. J. Metabolism of the endocannabinoids anandamide and 2-arachidonoyl glycerol, a review, with emphasis on the pharmacology of fatty acid amide hydrolase, a possible target for the treatment of neurodegenerative diseases and pain Curr. Med. Chem. Cent. Nerv. Sys. Agents 2004 4 161 174 review
40. Freund T. F. I. Katona D. Piomelli Role of endogenous cannabinoids in synaptic signaling Physiol. Rev. 2003 83 1017 1066 review
41. Fride E. C. Feigin D. E. Ponde A. Breuer L. Hanus N. Arshavsky R. Mechoulam (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only Eur. J. Pharmacol. 2004 506 179 188
42. Gaoni Y. R. Mechoulam Isolation, structure, and partial synthesis of an active constituent of hashish J. Amer. Chem. Soc. 1964 86 1646 1647
43. Giuffrida A. L. H. Parsons T. M. Kerr F. Rodríguez de Fonseca M. Navarro D. Piomelli Dopamine activation of endogenous cannabinoid signaling in dorsal striatum Nature Neurosci. 1999 2 358 363
44. Glaser S. T. M. Kaczocha D. G. Deutsch Anandamide transport: a critical review Life Sci. 2005 77 1584 1604 review
45. Glaser S. T. N. A. Abumrad F. Fatade M. Kaczocha K. M. Studholme D. G. Deutsch Evidence against the presence of an anandamide transporter Proc. Natl. Acad. Sci. USA 2003 100 4269 4274
46. Glass M. J. Hong T. A. Sato M. D. Mitchell Misidentification of prostamides as prostaglandins J. Lipid Res. 2005 46 1364 1368
47. Gühring H. M. Hamza M. Sergejeva M. Ates C. E. Kotalla C. Ledent K. Brune A role for endocannabinoids in indomethacin-induced spinal antinociception Eur. J. Pharmacol. 2002 454 153 163
48. Gulyas A. I. B. F. Cravatt M. H. Bracey T. P. Dinh D. Piomelli F. Boscia T. F. Freund Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala Eur. J. Neurosci. 2004 20 441 458
49. Hajos N. S. Kathuria T. Dinh D. Piomelli T. F. Freund Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404 Eur. J. Neurosci. 2004 19 2991 2996
50. 2, a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. USA 1999 96 14228 14233
51. Hanus L. A. Gopher S. Almog R. Mechoulam Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor J. Med. Chem. 1993 36 3032 3034
52. Hanus L. S. Abu-Lafi E. Fride A. Breuer Z. Vogel D. E. Shalev I. Kustanovich R. Mechoulam 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor Proc. Natl. Acad. Sci. USA 2001 98 3662 3665
53. 2+ dependency for triggering retrograde endocannabinoid signal Neuron 2005 45 257 268
54. Hillard C. J. A. Jarrahian Accumulation of anandamide: evidence for cellular diversity Neuropharmacology 2005 48 1072 1078
55. Hillard C. J. A. Jarrahian Cellular accumulation of anandamide: consensus and controversy Brit. J. Pharmacol. 2003 140 802 808 review
56. Hillard C. J. W. S. Edgemond A. Jarrahian W. B. Campbell Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion J. Neurochem. 1997 69 631 638
57. Högestätt E. D. B. A. G. Jönsson A. Ermund D. A. Andersson H. Björk J. P. Alexander B. F. Cravatt A. I. Basbaum P. M. Zygmunt Conversion of acetaminophen to the bioactive N-acyl phenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system J. Biol. Chem. 2005 280 31405 31412
58. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin J. Pharmacol. Exp. Therap. 2004 308 446 453
59. Hohmann A. G. R. L. Suplita N. M. Bolton M. H. Neely D. Fegley R. Mangieri J. F. Krey J. M. Walker P. V. Holmes J. D. Crystal A. Duranti A. Tontini M. Mor G. Tarzia D. Piomelli An endocannabinoid mechanism for stress-induced analgesia Nature 2005 453 1108 1112
60. Holt S. C. J. Fowler Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH Naunyn-Schmiedebergs Arch. Pharmacol. 2003 367 237 244
61. Holt S. F. Comelli B. Costa C. J. Fowler Inhibitors of fatty acid amide hydrolase reduce carrageenan induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors Brit. J. Pharmacol. 2005 146 467 476
62. Holt S. D. Rocksén A. Bucht G. Petersen H. S. Hansen M. Valenti V. Di Marzo C. J. Fowler Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase Life Sci. 2004 76 461 472
63. Hopkins S. C. F. Wang Inhibitors of anandamide uptake lacking arachidonoyl chain. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2004 p. 103
64. House of Lords The United Kingdom Parliament 1998
65. Howlett A. C. F. Barth T. I. Bonner G. Cabral P. Casellas W. A. Devane C. C. Felder M. Herkenham K. Mackie B. R. Martin R. Mechoulam R. G. Pertwee International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 2002 54 161 202 review
66. Howlett A. C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds Life Sci. 1984 35 1803 1810
67. Huang S. M. T. Bisogno M. Trevisani A. Al-Hayani L. De Petrocellis F. Fezza M. Tognetto T. J. Petros J. F. Krey C. J. Chu J. D. Miller S. N. Davies P. Geppetti J. M. Walker V. Di Marzo An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors Proc. Natl. Acad. Sci. USA 2002 99 8400 8405
68. Huestis M. A. D. A. Gorelick S. J. Heishman K. L. Preston R. A. Nelson E. T. Moolchan R. A. Frank Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch. Gen. Psychiat. 2001 58 322 328
69. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids Proc. Natl. Acad. Sci. USA 2005 102 3093 3098
70. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc. Natl. Acad. Sci. USA 2003 100 10529 10533
71. Idris A. I. R. J. van't Hof I. R. Greig S. A. Ridge D. Baker R. A. Ross S. H. Ralston Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors Nature Med. 2005 11 774 779
72. 2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of β-hexosaminidase from skin slices in vitro Life Sci. 2006 78 598 606
73. Jung K.-M. R. Mangieri C. Stapleton J. Kim D. Fegley M. Wallace K. Mackie D. Piomelli Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors Mol. Pharmacol. 2005 68 1196 1202
74. Karanian D. A. Q. B. Brown A. Makriyannis T. A. Kosten B. A. Bahr Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity J. Neurosci. 2005 25 7813 7820
75. Kathuria S. S. Gaetani D. Fegley F. Valiño A. Duranti A. Tontini M. Mor G. Tarzia G. La Rana A. Calignano A. Giustino M. Tattoli M. Palmery V. Cuomo D. Piomelli Modulation of anxiety through blockade of anandamide hydrolysis Nature Med. 2003 9 76 81
76. Kim J. B. E. Alger Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus Nature Neurosci. 2004 7 697 698
77. Kondo S. T. Sugiura T. Kodaka N. Kudo K. Waku A. Tokumura Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis Arch. Biochem. Biophys. 1998 354 303 310
78. Kozak K. R. L. J. Marnett Oxidative metabolism of endocannabinoids Prostaglandins Leukotrienes Essent. Fatty Acids 2002 66 211 220 review
79. Kozak K. R. R. A. Gupta J. S. Moody C. Ji W. E. Boeglin R. N. DuBois A. R. Brash L. J. Marnett 15-Lipoxygenase metabolism of 2-arachidonoylglycerol. Generation of a peroxisome proliferator-activated receptor α agonist J. Biol. Chem. 2002 277 23278 23286
80. 1 cannabinoid receptor antagonists Curr. Opin. Drug Discov. Dev. 2004 7 498 506 review
81. 1 cannabinoid receptors Brit. J. Pharmacol. 2004 141 253 262
82. Lichtman A. H. C. C. Shelton T. Advani B. F. Cravatt Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia Pain 2004a 109 319 327
83. Lichtman A. H. D. Leung S. C. Shelton A. Saghatelian C. Hardouin D. L. Boger B. F. Cravatt Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity J. Pharmacol. Exp. Therap. 2004b 311 441 448
84. Liu J. L. Wang J. Harvey-White G. Kunos Novel anandamide biosynthetic pathway in RAW264.7 macrophages. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2005 p. 119
85. Lupica C. R. A. C. Riegel Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction Neuropharmacology 2005 48 1105 1116 review
86. Makara J. K. M. Mor D. Fegley S. I. Szabó S. Kathuria G. Astarita A. Duranti A. Tontini G. Tarzia S. Rivara T. F. Freund D. Piomelli Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus Nature Neurosci. 2005 8 1139 1141
87. 2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase C β4 signaling cascade in the cerebellum J. Neurosci. 2005 25 6826 6835
88. 2 cannabinoid receptor-mediated peripheral antinociception Pain 2001 93 239 245
89. Massa F. G. Marsicano H. Hermann A. Cannich K. Monory B. F. Cravatt G.-L. Ferri A. Sibaev M. Storr B. Lutz The endogenous cannabinoid system protects against colonic inflammation J. Clin. Invest. 2004 113 1202 1209
90. Matias I. J. Chen L. De Petrocellis. T. Bisogno A. Ligresti F. Fezza A. H.-P. Krauss L. Shi C. E. Protzman C. Li Y. Liang A. L. Nieves K. M. Kedzie R. M. Burk V. Di Marzo D. F. Woodward Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism J. Pharmacol. Exp. Therap. 2004 309 745 757
91. Matsuda L. A. S. J. Lolait M. J. Brownstein A. C. Young T. I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990 346 561 564
92. Mauler F. J. Mittendorf E. Horváth J. De Vry Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4, 4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties J. Pharmacol. Exp. Therap. 2002 302 359 368
93. McFarland M. J. A. C. Porter F. R. Rakhshan D. S. Rawat R. A. Gibbs E. L. Barker A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide J. Biol. Chem. 2004 279 41991 41997
94. McPartland J. M. Phylogenomic and chemotaxonomic analysis of the endocannabinoid system Brain Res. Rev. 2004 45 18 29 review
95. McVey D. C. P. C. Schmid H. H. O. Schmid H. R. Vigna Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1) J. Pharm. Exp. Therap. 2003 304 713 722
96. Mechoulam R S. Ben-Shabat L. Hanus M. Ligumsky N. E. Kaminski A. R. Schatz A. Gopher S. Almog B. R. Martin D. R. Compton R. G. Pertwee G. Griffin M. Bayewitch J. Barg Z. Vogel Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 1995 50 83 90
97. Melis M. S. Perra A. L. Muntoni G. Pillolla B. Lutz G. Marsicano V. DiMarzo G. L. Gessa M. Pistis Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons J. Neurosci. 2004 24 10707 10715
98. Montane E. M. Duran D. Capella A. Figueras Scientific drug information in newspapers: sensationalism and low quality. The example of therapeutic use of cannabinoids Eur. J. Clin. Pharmacol. 2005 61 475 477
99. Moore S. A. G. G. Nomikos A. K. Dickason-Chesterfield D. A. Schober J. M. Schaus B.-P. Ying Y.-C. Xu L. Phebus R. M. A. Simmons D. Li S. Iyengar C. C. Felder Identification of a high-affinity binding site involved in the transport of endocannabinoids Proc. Natl. Acad. Sci. USA 2005 102 17852 17857
100. Morozov Y. M. Y. Ben-Ari T. F. Freund The spatial and temporal pattern of fatty acid amide hydrolase expression in rat hippocampus during postnatal development Eur. J. Neurosci. 2004 20 459 466
101. 1 cannabinoid receptor-Gi protein interactions Mol. Pharmacol. 2005 67 2016 2024
102. Munro S. K. L. Thomas M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 1993 365 61 65
103. Natarajan V. P. C. Schmid P. V. Reddy H. H. O. Schmid Catabolism of N-acylethanolamine phospholipids by dog brain preparations J. Neurochem. 1984 42 1613 1619
104. Nirodi C. S. B. C. Crews K. R. Kozak J. D. Morrow L. J. Marnett The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells Proc. Natl. Acad. Sci. USA 2004 101 1840 1845
105. Oddi S. M. Bari N. Battista D. Barsacchi I. Cozzani M. Maccarrone Confocal microscopy and biochemical analysis reveals spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes Cell. Mol. Life Sci. 2005 62 386 395
106. Okamoto Y. J. Morishita K. Tsuboi T. Tonai N. Ueda Molecular characterization of a phospholipase D generating anandamide and its congeners J. Biol. Chem. 2004 279 5298 5305
107. Ortega-Gutiérrez S. E. G. Hawkins A. Viso M. L. López-Rodríguez B. F. Cravatt Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake Biochemistry 2004 43 8184 8190
108. Panikashvili D. C. Simeonidou S. Ben-Shabat L. Hanus A. Breuer R. Mechoulam E. Shohami An endogenous cannabinoid (2-AG) is neuroprotective after brain injury Nature 2001 413 527 531
109. Pertwee R. G. Cannabinoid receptors and pain Progr. Neurobiol. 2001 63 569 611 review
110. Porter A. C. J. M. Sauer M. D. Knierman G. W. Becker M. J. Berna J. Bao G. G. Nomikos P. Carter F. P. Bymaster A. B. Leese C. C. Felder Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor J. Pharmacol. Exp. Therap. 2002 301 1020 1024
111. Pryce G. D. Baker Emerging properties of cannabinoid medicines in management of multiple sclerosis Trends Neurosci. 2005 28 272 276 review
112. Ramírez B. G. C. Blázquez T. Gómez del Pulgar M. Guzmán M. L. de Ceballos Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J. Neurosci. 2005 25 1904 1913
113. Razdan R. K. Structure-activity relationships in cannabinoids Pharmacol. Rev. 1986 38 75 149 review
114. Reynolds J. R. On the therapeutic uses and toxic effects of Cannabis indica Lancet 1890 135 637 638
115. Rockwell C. E. N. E. Kaminski A cyclooxygenase metabolite of anandamide causes inhihbition of interleukin-2 secretion in murine splenocytes J. Pharmacol. Exp. Therap. 2004 311 683 690
116. 2 ethanolamide J. Pharmacol. Exp. Therap. 2002 301 900 907
117. Rouzer C. A. L. J. Marnett Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymozan stimulus J. Biol. Chem. 2005 280 26690 26700
118. Shoemaker J. L. M. B. Ruckle P. R. Mayeux P. L. Prather Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors J. Pharmacol. Exp. Therap. 2005 315 828 838
119. Sjögren S. E. Ryberg A. Lindblom N. Larsson A. Åstrand S. Hjorth A.-K. Andersson T. Groblewski P. Greasley A new receptor for cannabinoid ligands. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2005 p. 106
120. Steffens S. N. R. Veillard C. Arnaud G. Pelli F. Burger C. Staub A. Zimmer J.-L. Frossard F. Mach, F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice Nature 2005 434 782 786
121. Stella N. D. Piomelli Receptor-dependent formation of endogenous cannabinoids in cortical neurons Eur. J. Pharmacol. 2001 425 189 196
122. Stella N. P. Schweitzer D. Piomelli A second endogenous cannabinoid that modulates long-term potentiation Nature 1997 388 773 778
123. Sugiura T. S. Kondo A. Sugukawa S. Nakane A. Shinoda K. Itoh A. Yamashita K. Waku 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 1995 215 89 97
124. 2 and lysophospholipase D Biochem. J. 2004 380 749 756
125. Szabo B. M. J. Urbanski V. Di Marzo The role of 2-arachidonoylglycerol in retrograde signaling. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2005 p. 14
126. Valenzano K. J. L. Tafesse G. Lee J. E. Harrisson J. M. Boulet S. L. Gottshall L. Mark M. S. Pearson W. Miller S. Shan L. Rabadi Y. Rotshteyn S. M. Chaffer P. I. Turchin D. A. Elsemore M. Toth L. Koetzner G. T. Whiteside Pharmacological and pharmakokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy Neuropharmacology 2005 48 658 672
127. 2+ influx via TRPV1 channels EMBO J. 2005 24 3026 3037
128. Vandevoorde S. C. J. Fowler Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate Brit. J. Pharmacol. 2005 165 885 893
129. Van Gaal L. F. A. M. Rissanen A. J. Scheen O. Ziegler S. Rössner for the RIO-Europe Study Group Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 2005 365 1389 1397
130. Velasco G. I. Galve-Roperh C. Sánchez C. Blázquez M. Gúzman Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 2004 47 315 323 review
131. Wade D. T. P. Robson H. House P. Makela J. Aram A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms Clin. Rehab. 2003 17 21 29
132. Wahn H. J. Wolf F. Kram S. Frantz J. A. Wagner The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs Amer. J. Physiol. 2005 289 H2491 H2496
133. Walker J. M. S. M. Huang N. M. Strangman K. Tsou M. C. Sañudo-Peña Pain modulation by release of the endogenous cannabinoid anandamide Proc. Natl. Acad. Sci. USA 1999 96 12198 12203
134. Walter L. N. Stella Cannabinoids and neuroinflammation Brit. J. Pharmacol. 2004 141 775 785 review
135. Weber A. J. Ni K.-H. J. Ling A. Acheampong D. D.-S. Tang-Liu R. Burk B. F. Cravatt D. Woodward Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry J. Lipid Res. 2004 45 757 763
136. 1 receptor mediated mechanism Proc. Brit. Pharm. Soc. 2005
137. G93A transgenic mice J. Neurochem. 2004 89 1555 1557
138. Woodward D. F. A. H.-P. Krauss A. L. Nieves C. E. Protzman J.-W. Wang Y. Donde K. Landsverk C. Struble First report on a prostaglandin-ethanolamide (prostamide) receptor antagonist AGN204396. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2005 p. 70
139. 2α in FAAH -/- and FAAH +/+ mice. Symposium on the Cannabinoids International Cannabinoid Research Society Burlington, Vermont 2004 78
140. Wotherspoon G. A. Fox P. McIntyre S. Colley S. Bevan J. Winter Peripheral nerve injury induces canabinoid receptor 2 protein expression in rat sensory neurons Neuroscience 2005 35 235 245
141. Zajicek J. P. Fox H. Sanders D. Wright J. Vickery A. Nunn A. Thompson on behalf of the UK MS Research Group Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial Lancet 2003 362 1517 1526
142. Zhong L. L. Geng Y. Njie W. Feng Z.-H. Song CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility Invest. Ophthal. Vis. Sci. 2005 46 1988 1992
143. Zygmunt P. M. J. Petersson D. A. Andersson H. Chuang M. Sørgard V. Di Marzo D. Julius E. D. Högestätt Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide Nature 1999 400 452 457